Are hypoglycaemia and other adverse effects similar among sulphonylureas? (Q31122704)

29 June 2017

1 reference

title

Are hypoglycaemia and other adverse effects similar among sulphonylureas? (English)

1 reference

29 June 2017

1 reference

2

Jaime J Caro

1 reference

29 June 2017

Maribel Salas

1

1 reference

29 June 2017

1 January 2002

1 reference

29 June 2017

Toxicological Reviews

1 reference

29 June 2017

21

1 reference

29 June 2017

4

1 reference

29 June 2017

205-217

1 reference

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

29 June 2017

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Fifteen years' experience with pancreas transplantation with pancreaticoenterostomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

The sulphonylurea receptor may be an ATP-sensitive potassium channel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Utilization of oral hypoglycemic agents in a drug-insured U.S. population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Differences in antidiabetic drug utilisation between three different health systems in the same national region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Individual sulfonylureas and serious hypoglycemia in older people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Double blind clinical and laboratory study of hypoglycaemia with human and porcine insulin in diabetic patients reporting hypoglycaemia unawareness after transferring to human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Psychobehavioral metabolic parameters of severe hypoglycemic episodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

The psychosocial impact of severe hypoglycemic episodes on spouses of patients with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Perceived symptoms in the recognition of hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

21 January 2018

Living with hypoglycemia

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Rates of hypoglycemia in users of sulfonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Hypoglycemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Drugs inducing hypoglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

The crux of the UGDP. Spurious results and biologically inappropriate data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Cardiovascular effects of conventional sulfonylureas and glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

The sulfonylurea controversy: more questions from the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

ATP-regulated K+ channels in cardiac muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Pancreatic and extrapancreatic sulfonylurea receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Meglitinide analogues in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Sulfonylurea receptors and mechanism of sulfonylurea action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Mechanisms of the glycaemic effects of sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Reduction of ischemic K+ loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Management of newly diagnosed non-insulin-dependent (type 2) diabetes mellitus: a retrospective audit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Chlorpropamide hyponatremia: drug-induced inappropriate antidiuretic-hormone activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Mechanism of chlorpropamide-induced antidiuresis in man: Evidence for release of ADH and enhancement of peripheral action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

21 January 2018

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

Different Binding Properties and Affinities for ATP and ADP among Sulfonylurea Receptor Subtypes, SUR1, SUR2A, and SUR2B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256197

21 January 2018

Identifiers

DOI

10.1007/BF03256197

1 reference

PubMed ID

12503254

Dimensions Publication ID

29 June 2017

0 references

1 reference

PubMed ID

12503254